Audit: QRS - Glutamine for Health & Longevity

Audit conducted on 22/09/2026 17:52 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	84
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every gate item, tier item, protocol cell, marker row and qualitative item traces to an ER passage.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative tiers carry the ER’s own speculative headings; no hedged claim is hardened.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Avoidance list reproduced as contraindications; cautions remain cautions.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from Key Interactions & Contraindications; tiers only from Expected Benefits / Potential Risks & Side Effects.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Register and vocabulary (“gut”, “mouth and throat ulceration”, “split dosing dominates”) mirror the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Balanced: clear where evidence is absent, clear where it holds.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Descriptive noun phrases throughout, no prescriptions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives directed at a reader.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Protocol and monitoring cells state what trials and protocols used, not what to do.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second person anywhere.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to biomarker names, which the ER also uses verbatim.
2.8	Information is presented in a concise and very compact manner	🟢	All items are short noun phrases; no sentence padding.
2.9	It DOES NOT address the reader directly	🟢	Confirmed, no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content selection (dose, timing, biomarker panel) suits this audience.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker panel and 3×/day eight-week regimen are retained without simplification.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Depth of monitoring and gate detail exceeds general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	ICU mortality signal is carried at the ER’s own High tier and bounded by the matching contraindication.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not occur; title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	“gastrointestinal symptoms”, “empty stomach”, “free L-glutamine powder”; no lay route-of-administration phrasing.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings present verbatim (lines 439, 476, 518, 538, 552, 571, 590, 594–596, 709).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names present; marker_#_* expanded to 1–9 and qualitative_item_# to 1–6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit", website="full_review" untouched; CSS, head and footer byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard clinical gut protocol”, “Sports and general-wellness approach”, “Single versus split dosing” are verbatim ER bold labels; all nine marker names verbatim from the ER table.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and marker labels are unmodified; time-to-effect labels are derived from the ER’s own Time to effect prose, which supplies no bold labels.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the file; the ER’s “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Gate items, tier lines, marker rows and cadence are all trimmed to the template’s per-section budget.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated on the page.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: glutamine_2026-0909-0508_Opus_ER.md, matching the ER’s own filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: 26.9.22, matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: 2026-0922-1713.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” carries no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 21: “Glutamine for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 416: “Glutamine for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 420: 09/22/2026, matching qrs_creation_date: 2026-0922-1713.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 424: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template’s standard subline.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Glutamine is an amino acid the body makes, sold as a powder for gut and recovery support.”
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Tracks the ER Conclusion: depleted-pool framing, the two clearest settings, the modest metabolic gains, the unsupported claims, tolerability.
7.3	[at_a_glance] is no longer than 70 words	🟢	58 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to ER lines 487–489, with “gut and recovery support” additionally supported at lines 369 and 435.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“inflammation marker”, “gut lining”, “mouth and throat”; no acronyms, no clinical-register words.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial named or sized.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Only the qualitative “improve modestly”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from the “Populations who should avoid Glutamine” list, ER lines 331–339.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoidance bullets are represented, one to one.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements, lines 541–547.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes and no trailing clauses; the ER’s “in whom reactions are reported at ordinary doses” was correctly stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Child-Pugh B or C, <30 mL/min/1.73 m², two or more organ systems, first 24 hours, asymptomatic OTC carriers — all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	Drawn from ER lines 313–329.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of nine ER bullets carried; anticonvulsants and glutamine-antagonist chemotherapy correctly omitted as contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements, lines 555–561.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is a drug class plus its parenthetical; all mechanism and mitigation text stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named example drugs retained for glucose-lowering agents, competing amino acids and NSAIDs; somatropin and lactulose/rifaximin keep their glosses.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine such entries and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to ER Therapeutic Protocol bullets (lines 363, 369, 373, 375).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The trial-validated gut regimen, the consumer dose range, and the single-versus-split dosing pattern.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER’s Therapeutic Protocol section supplies twelve bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Mucositis protection, acute glycemic/hormone response, and gut symptom relief — the three aspects named in ER line 416.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Mucositis (High, first ER benefit), glycemic control (High, second), post-infectious IBS relief (Medium) — correct descending order.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct aspects are present in the ER.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated from ER lines 373 and 416.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides a dedicated “Time to effect” bullet at line 416.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen ER benefit headings are represented in their own tiers.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 520–531).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each tier is a comma-separated list of condensed ER headings; no magnitudes or “⚠️ Conflicted” markers carried.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits line.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items (3 / 3 / 3 / 4).

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven ER risk headings are represented in their own tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 573–584).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Condensed ER headings only; REDOXS/MetaPlus detail and the “⚠️ Conflicted” marker correctly dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks line.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items (2 / 1 / 2 / 2).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER Monitoring Protocol & Defining Success biomarker table, lines 446–456.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows present as marker_1–marker_9, names verbatim and targets preserved.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 703 reproduces the 8–12 week / 6 month / annual cadence and all three early-check triggers from ER line 444.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER’s qualitative marker list, lines 460–465.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers present as qualitative_item_1–6, wording unchanged.

Issues 22/09/2026 17:52

Pass rate 100.00%. No issues found.

Issues 22/09/2026 17:45

1. 2.7 — Unnecessary “mucositis” jargon: time_1_label (line 482) reads “Mucositis protection” while benefits_high (line 521) renders the same ER fact in plain language as “mouth and throat ulceration”, making the specialist term both unnecessary and internally inconsistent.

Fixes 22/09/2026 17:45

1. 2.7 — Plain-language time-to-effect label: Replaced the specialist term in time_1_label, from “Mucositis protection” to “Mouth and throat protection”, and adjusted time_1_sub from “Mouth and throat ulceration severity” to “Ulceration severity during cancer treatment” to avoid repetition; both wordings are supported by the ER’s benefit heading and line 157.

Issues 22/09/2026 17:39

1. 8.5 — “history of” qualifier dropped: The contraindication at line 546 reads “Treated epilepsy, or bipolar disorder with mania”, while ER line 338 specifies “bipolar disorder with a history of mania” — the dropped qualifier narrows the gate to currently manic patients.
2. 11.4 — time_2_sub misses hormone response: [time_2_sub] at line 499 reads “Acute post-meal glucose response”, covering only half of its own label and of ER line 416, which pairs “Glycaemic and hormone responses are acute, within 90 minutes”.

Fixes 22/09/2026 17:39

1. 8.5 — Mania qualifier restored: Changed the contraindication from “bipolar disorder with mania” to “bipolar disorder with a history of mania”, matching the ER’s own wording and restoring the gate’s original scope.
2. 11.4 — Hormone response added to time cell: Changed [time_2_sub] from “Acute post-meal glucose response” to “Acute post-meal glucose and hormone response”, so the cell covers both halves of its label and of the ER’s time-to-effect statement.

Issues 22/09/2026 17:32

1. 2.15 — Consumer-grade glycemic wording: The at-a-glance lede (line 432) says “Fasting blood sugar and an inflammation marker improve modestly”; “blood sugar” is consumer-grade where the sheet’s own clinical register uses “Fasting glucose” (line 624).

Fixes 22/09/2026 17:32

1. 2.15 — Consumer-grade glycemic wording: Replaced “Fasting blood sugar” with “Fasting glucose” in the at-a-glance lede, matching the clinical register used in the Monitoring table.

Issues 22/09/2026 17:27

1. 1.3 — Muscle claim over-generalized: [at_a_glance] line 432 states “Muscle claims are unsupported”, but the ER Conclusion (line 487) restricts the null result to “muscle size and athletic performance” and notes a small older-adult strength gain — which the QRS itself lists as a Medium benefit at line 524.

Fixes 22/09/2026 17:27

1. 1.3 — Muscle claim scope restored: Changed [at_a_glance] from “Muscle claims are unsupported” to “Claims for muscle size and athletic performance are unsupported”, matching the ER Conclusion’s scope and removing the contradiction with the Medium-tier older-adult knee strength benefit.

Issues 22/09/2026 17:20

1. 4.5 — Sheet overruns one A4 page: Estimated rendered height is ~1,920 px against ~1,032 px of A4 space, roughly 1.9 pages. Monitoring (16 wrapped lines for 9 markers; marker_7_target line 671, marker_9_target line 693 and the cadence at line 703 each wrap to two lines) and Contraindications (16 wrapped lines for 7 items; lines 543–545 each wrap to three) are the least condensed, with at_a_glance (line 432, 68 words) and action_3_sub (line 471, 127 characters) also uncondensed.
2. 8.4 — Chemotherapy agent names added: Line 544 appends “(DON, sirpiglenastat/DRP-104)” to the malignancy item, an elaboration absent from the ER’s own avoid-list bullet (ER line 336) where “glutamine-antagonist chemotherapy” already identifies the class.

Fixes 22/09/2026 17:20

1. 8.4 — Chemotherapy agent names removed: Stripped the “(DON, sirpiglenastat/DRP-104)” elaboration from the malignancy contraindication, which now reads “Active gastrointestinal or hepatic malignancy, or glutamine-antagonist chemotherapy” in line with the ER’s own avoid-list bullet.
2. 4.5 — Contraindications condensed: Rewrote five of the seven [stop_items] more tightly (e.g. “Cirrhosis of Child-Pugh Class B or C, or any history of hepatic encephalopathy” → “Child-Pugh B or C cirrhosis, or prior hepatic encephalopathy”), cutting the gate from 16 wrapped lines to 12 while preserving every severity class, threshold and time window.
3. 4.5 — Monitoring cells condensed: Shortened four “Why” rationales, the alanine aminotransferase target (“Below 20 U/L in men, below 18 U/L in women” → “Below 20 U/L (18 women)”), the lactulose-to-mannitol target and the cadence line, taking the table from 16 wrapped lines to 11 with all nine markers retained.
4. 4.5 — At-a-glance shortened: Reduced the lede from 68 to 54 words (5 wrapped lines to 4) while keeping the opening statement of what glutamine is, both clearest indications, the glycemic and inflammation signals, the failed muscle claims and tolerability.
5. 4.5 — Protocol and time subs trimmed: Cut [action_3sub] from 120 to 68 characters (4 wrapped lines to 2) and tightened all three [time#_sub] cells; [time_2_sub] became “Acute post-meal glucose response”, removing the implication that the fasting-glucose effect is acute.
6. 4.5 — Key interactions tightened: Shortened two [caution_items] parentheticals, dropping the gate from 12 wrapped lines to 10 with every ER example-drug list still represented.
7. 4.5 — Residual overflow noted: Estimated height fell from ~1,920 px to ~1,706 px against ~1,032 px of A4 space; the remainder is structural, since items 8.2, 9.2, 12.1, 13.1, 14.2 and 15.2 require all 7 contraindications, 7 interactions, 8 benefit/risk tiers, 9 biomarkers and 6 qualitative markers to be listed.